Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies
Abstract Enhancer of zeste homolog 2 (EZH2), an enzymatic subunit of PRC2 complex, plays an important role in tumor development and progression through its catalytic and noncatalytic activities. Overexpression or gain-of-function mutations of EZH2 have been significantly associated with tumor cell p...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2023-01-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-022-01240-3 |
| _version_ | 1797945666574483456 |
|---|---|
| author | Husheng Mei Hong Wu Jing Yang Bin Zhou Aoli Wang Chen Hu Shuang Qi Zongru Jiang Fengming Zou Beilei Wang Feiyang Liu Yongfei Chen Wenchao Wang Jing Liu Qingsong Liu |
| author_facet | Husheng Mei Hong Wu Jing Yang Bin Zhou Aoli Wang Chen Hu Shuang Qi Zongru Jiang Fengming Zou Beilei Wang Feiyang Liu Yongfei Chen Wenchao Wang Jing Liu Qingsong Liu |
| author_sort | Husheng Mei |
| collection | DOAJ |
| description | Abstract Enhancer of zeste homolog 2 (EZH2), an enzymatic subunit of PRC2 complex, plays an important role in tumor development and progression through its catalytic and noncatalytic activities. Overexpression or gain-of-function mutations of EZH2 have been significantly associated with tumor cell proliferation of triple-negative breast cancer (TNBC) and diffuse large B-cell lymphoma (DLBCL). As a result, it has gained interest as a potential therapeutic target. The currently available EZH2 inhibitors, such as EPZ6438 and GSK126, are of benefit for clinical using or reached clinical trials. However, certain cancers are resistant to these enzymatic inhibitors due to its noncatalytic or transcriptional activity through modulating nonhistone proteins. Thus, it may be more effective to synergistically degrade EZH2 in addition to enzymatic inhibition. Here, through a rational design and chemical screening, we discovered a new irreversible EZH2 inhibitor, IHMT-337, which covalently bounds to and degrades EZH2 via the E3 ligase CHIP-mediated ubiquitination pathway. Moreover, we revealed that IHMT-337 affects cell cycle progression in TNBC cells through targeting transcriptional regulating of CDK4, a novel PRC2 complex- and enzymatic activity-independent function of EZH2. More significantly, our compound inhibits both DLBCL and TNBC cell proliferation in different preclinical models in vitro and in vivo. Taken together, our findings demonstrate that in addition to enzymatic inhibition, destroying of EZH2 by IHMT-337 could be a promising therapeutic strategy for TNBC and other malignancies that are independent of EZH2 enzymatic activity. |
| first_indexed | 2024-04-10T20:59:47Z |
| format | Article |
| id | doaj.art-4b56dff9cd41484db8675c13e8356cf0 |
| institution | Directory Open Access Journal |
| issn | 2059-3635 |
| language | English |
| last_indexed | 2024-04-10T20:59:47Z |
| publishDate | 2023-01-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Signal Transduction and Targeted Therapy |
| spelling | doaj.art-4b56dff9cd41484db8675c13e8356cf02023-01-22T12:26:23ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352023-01-018111310.1038/s41392-022-01240-3Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignanciesHusheng Mei0Hong Wu1Jing Yang2Bin Zhou3Aoli Wang4Chen Hu5Shuang Qi6Zongru Jiang7Fengming Zou8Beilei Wang9Feiyang Liu10Yongfei Chen11Wenchao Wang12Jing Liu13Qingsong Liu14Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of SciencesAbstract Enhancer of zeste homolog 2 (EZH2), an enzymatic subunit of PRC2 complex, plays an important role in tumor development and progression through its catalytic and noncatalytic activities. Overexpression or gain-of-function mutations of EZH2 have been significantly associated with tumor cell proliferation of triple-negative breast cancer (TNBC) and diffuse large B-cell lymphoma (DLBCL). As a result, it has gained interest as a potential therapeutic target. The currently available EZH2 inhibitors, such as EPZ6438 and GSK126, are of benefit for clinical using or reached clinical trials. However, certain cancers are resistant to these enzymatic inhibitors due to its noncatalytic or transcriptional activity through modulating nonhistone proteins. Thus, it may be more effective to synergistically degrade EZH2 in addition to enzymatic inhibition. Here, through a rational design and chemical screening, we discovered a new irreversible EZH2 inhibitor, IHMT-337, which covalently bounds to and degrades EZH2 via the E3 ligase CHIP-mediated ubiquitination pathway. Moreover, we revealed that IHMT-337 affects cell cycle progression in TNBC cells through targeting transcriptional regulating of CDK4, a novel PRC2 complex- and enzymatic activity-independent function of EZH2. More significantly, our compound inhibits both DLBCL and TNBC cell proliferation in different preclinical models in vitro and in vivo. Taken together, our findings demonstrate that in addition to enzymatic inhibition, destroying of EZH2 by IHMT-337 could be a promising therapeutic strategy for TNBC and other malignancies that are independent of EZH2 enzymatic activity.https://doi.org/10.1038/s41392-022-01240-3 |
| spellingShingle | Husheng Mei Hong Wu Jing Yang Bin Zhou Aoli Wang Chen Hu Shuang Qi Zongru Jiang Fengming Zou Beilei Wang Feiyang Liu Yongfei Chen Wenchao Wang Jing Liu Qingsong Liu Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies Signal Transduction and Targeted Therapy |
| title | Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies |
| title_full | Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies |
| title_fullStr | Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies |
| title_full_unstemmed | Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies |
| title_short | Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies |
| title_sort | discovery of ihmt 337 as a potent irreversible ezh2 inhibitor targeting cdk4 transcription for malignancies |
| url | https://doi.org/10.1038/s41392-022-01240-3 |
| work_keys_str_mv | AT hushengmei discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT hongwu discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT jingyang discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT binzhou discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT aoliwang discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT chenhu discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT shuangqi discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT zongrujiang discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT fengmingzou discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT beileiwang discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT feiyangliu discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT yongfeichen discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT wenchaowang discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT jingliu discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies AT qingsongliu discoveryofihmt337asapotentirreversibleezh2inhibitortargetingcdk4transcriptionformalignancies |